Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS

Retrovirology

Volumn 4, Issue , 2007, Pages

  Sterjovski, Jasminka ^a,b   Churchill, Melissa J ^a,b   Ellett, Anne ^a   Gray, Lachlan R ^a,c   Roche, Michael J ^a   Dunfee, Rebecca L ^d   Purcell, Damian F J ^c   Saksena, Nitin ^e   Wang, Bin ^e   Sonza, Secondo ^a,b   Wesselingh, Steven L ^a,b,c   Karlsson, Ingrid ^f   Fenyo, Eva Maria ^f   Gabuzda, Dana ^d,g   Cunningham, Anthony L ^e   Gorry, Paul R ^a,b,c  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e WESTMEAD HOSPITAL   (Australia)

^f LUND UNIVERSITY   (Sweden)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ASPARAGINE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; ENFUVIRTIDE; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G1 ANTIBODY; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO TERMINAL SEQUENCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BINDING SITE; BLOOD ANALYSIS; CELL FUSION; CONTROLLED STUDY; ENZYME GLYCOSYLATION; ENZYME KINETICS; ENZYME STABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONGITUDINAL STUDY; MOLECULAR MODEL; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PATIENT REFERRAL; PREVALENCE; PROTEIN STRUCTURE; PROTEIN VARIANT; PSEUDOTYPING; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; SYMPTOMATOLOGY; VIRUS ISOLATION; VIRUS NEUTRALIZATION; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MONONUCLEAR CELL; PATHOGENICITY; PHYSIOLOGY; VIROLOGY; VIRULENCE; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIGENS, CD4; ASPARAGINE; CELL FUSION; CELLS, CULTURED; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MODELS, MOLECULAR; RECEPTORS, CCR5; VIRULENCE; VIRUS ATTACHMENT;

EID: 38949160397     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-4-89     Document Type: Article

References (96)

1. Berger EA Murphy PM Farber JM Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease Annu Rev Immunol 1999, 17:657-700 10.1146/annurev.immunol.17.1.657 10358771
2. Doms RW Trono D The plasma membrane as a combat zone in the HIV battlefield Genes Dev 2000, 14(21):2677-2688 10.1101/gad.833300 11069884
3. Moore JP Kitchen SG Pugach P Zack JA The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection AIDS Res Hum Retroviruses 2004, 20(1):111-126 10.1089/088922204322749567 15000703
4. Connor RI Sheridan KE Ceradini D Choe S Landau NR Change in coreceptor use coreceptor use correlates with disease progression in HIV-1--infected individuals J Exp Med 1997, 185(4):621-628 10.1084/ jem.185.4.621 9034141
5. Bjorndal A Deng H Jansson M Fiore JR Colognesi C Karlsson A Albert J Scarlatti G Littman DR Fenyo EM Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype J Virol 1997, 71(10):7478-7487 192094 9311827
6. Karlsson A Parsmyr K Aperia K Sandstrom E Fenyo EM Albert J MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance J Infect Dis 1994, 170(6):1367-1375 7995974
7. Koot M Keet IP Vos AH de Goede RE Roos MT Coutinho RA Miedema F Schellekens PT Tersmette M Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS Ann Intern Med 1993, 118(9):681-688 8096374
8. Tersmette M Gruters RA de Wolf F de Goede RE Lange JM Schellekens PT Goudsmit J Huisman HG Miedema F Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates J Virol 1989, 63(5):2118-2125 250628 2564898
9. de Roda Husman AM Schuitemaker H Chemokine receptors and the clinical course of HIV-1 infection Trends Microbiol 1998, 6(6):244-249 10.1016/ S0966-842X(98)01249-9 9675802
10. Jansson M Backstrom E Bjorndal A Holmberg V Rossi P Fenyo EM Popovic M Albert J Wigzell H Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS J Hum Virol 1999, 2(6):325-338 10774549
11. Jansson M Popovic M Karlsson A Cocchi F Rossi P Albert J Wigzell H Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates Proc Natl Acad Sci USA 1996, 93(26):15382-15387 26413 8986820 10.1073/pnas.93.26.15382
12. de Roda Husman AM van Rij RP Blaak H Broersen S Schuitemaker H Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression J Infect Dis 1999, 180(4):1106-1115 10.1086/314987 10479137
13. Karlsson I Antonsson L Shi Y Oberg M Karlsson A Albert J Olde B Owman C Jansson M Fenyo EM Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype J Virol 2004, 78(21):11807-11815 523262 15479822 10.1128/ JVI.78.21.11807-11815.2004
14. Koning FA Kwa D Boeser-Nunnink B Dekker J Vingerhoed J Hiemstra H Schuitemaker H Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection J Infect Dis 2003, 188(6):864-872 10.1086/377105 12964118
15. Gorry PR Churchill M Crowe SM Cunningham AL Gabuzda D Pathogenesis of macrophage tropic HIV Curr HIV Res 2005, 3(1):53-60 10.2174/ 1570162052772951 15638723
16. Sodroski J Goh WC Rosen C Campbell K Haseltine WA Role of the HTLV-III/ LAV envelope in syncytium formation and cytopathicity Nature 1986, 322(6078):470-474 10.1038/322470a0 3016552
17. LaBonte JA Patel T Hofmann W Sodroski J Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells J Virol 2000, 74(22):10690-0698 110943 11044113 10.1128/JVI.74.22.10690-10698.2000
18. Cayabyab M Karlsson GB Etemad-Moghadam BA Hofmann W Steenbeke T Halloran M Fanton JW Axthelm MK Letvin NL Sodroski JG Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2) J Virol 1999, 73(2):976-984 103917 9882298
19. Karlsson GB Halloran M Li J Park IW Gomila R Reimann KA Axthelm MK Iliff SA Letvin NL Sodroski J Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys J Virol 1997, 71(6):4218-4225 191636 9151808
20. Karlsson GB Halloran M Schenten D Lee J Racz P Tenner-Racz K Manola J Gelman R Etemad-Moghadam B Desjardins E Wyatt R Gerard NP Marcon L Margolin D Fanton J Axthelm MK Letvin NL Sodroski J The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques J Exp Med 1998, 188(6):1159-1171 10.1084/jem.188.6.1159 9743534
21. Stephens EB Joag SV Sheffer D Liu ZQ Zhao L Mukherjee S Foresman L Adany I Li Z Pinson D Narayan O Initial characterization of viral sequences from a SHIV-inoculated pig-tailed macaque that developed AIDS J Med Primatol 1996, 25(3);175-185 8892038
22. Stephens EB Mukherjee S Sahni M Zhuge W Raghavan R Singh DK Leung K Atkinson B Li Z Joag SV Liu ZQ Narayan O A cell-free stock of simian-human immunodeficiency virus that causes AIDS in pig-tailed macaques has a limited number of amino acid substitutions in both SIVmac and HIV-1 regions of the genome and has offered cytotropism Virology 1997, 231(2):313-321 10.1006/viro.1997.8534 9168893
23. Liu ZQ Muhkerjee S Sahni M McCormick-Davis C Leung K Li Z Gattone VH 2nd Tian C Doms RW Hoffman TL Raghavan R Narayan O Stephens EB Derivation and biological characterization of a molecular clone of SHIV(KU-2) that causes AIDS, neurological disease, and renal disease in rhesus macaques Virology 1999, 260(2):295-307 10.1006/viro.1999.9812 10417264
24. Etemad-Moghadam B Rhone D Steenbeke T Sun Y Manola J Gelman R Fanton JW Racz P Tenner-Racz K Axthelm MK Letvin NL Sodroski J Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus J Virol 2001, 75(12):5646-5655 114277 11356972 10.1128/JVI.75.12.5646-5655.2001
25. Etemad-Moghadam B Sun Y Nicholson EK Fernandes M Liou K Gomila R Lee J Sodroski J Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo J Virol 2000, 74(9):4433-4440 111962 10756060 10.1128/ JVI.74.9.4433-4440.2000
26. Si Z Gorry P Babcock G Owens CM Cayabyab M Phan N Sodroski J Envelope glycoprotein determinants of increased entry in a pathogenic simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys AIDS Res Hum Retroviruses 2004, 20(2):163-173 10.1089/ 088922204773004888 15018704
27. Gonzalez-Scarano F Martin-Garcia J The neuropathogenesis of AIDS Nat Rev Immunol 2005 5(1):69-81 10.1038/nri1527 15630430
28. Glushakova S Baibakov B Margolis LB Zimmerberg J Infection of human tonsil histocultures: A model for HIV pathogenesis Nature Med 1995, 1(12):1320-1322 10.1038/nm1295-1320 7489416
29. Glushakova S Grivel JC Fitzgerald W Sylwester A Zimmerberg J Margolis LB Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency Nature Med 1998, 4(3):346-349 10.1038/nm0398-346 9500611
30. Picchio GR Gulizia RJ Wehrly K Chesebro B Mosier DE The cell tropism of human immunodeficiency virus type 1 determines the kinetics of plasma viremia in SCID mice reconstituted with human peripheral blood leukocytes J Virol 1998 72(3):2002-2009 109493 9499054
31. Harouse JM Gettie A Tan RC Blanchard J Cheng-Mayer C Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs Science 1999, 284(5415):816-819 10.1126/science.284.5415.816 10221916
32. Fais S Lapenta C Santini SM Spada M Parlato S Logozzi M Rizza P Belardelli F Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection J Virol 1999, 73(8):6453-6459 112726 10400739
33. Grivel JC Margolis LB CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue Nature Med 1999, 5(3):344-346 10.1038/6565 10086394
34. Li S Juarez J Alali M Dwyer D Collman R Cunningham A Naif HM Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates J Virol 1999, 73(12):9741-9755 113021 10559284
35. Tuttle DL Anders CB Aquino-De Jesus MJ Poole PP Lamers SL Briggs DR Pomeroy SM Alexander L Peden KW Andiman WA Sleasman JW Goodenow MM Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children AIDS Res Hum Retroviruses 2002, 18(5):353-362 10.1089/ 088922202753519133 11897037
36. Gray L Sterjovski J Churchill M Ellery P Nasr N Lewin SR Crowe SM Wesselingh S Cunningham AL Gorry PR Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome Virology 2005, 337(2):384-398 10.1016/j.virol.2005.04.034 15916792
37. Kwa D Vingerhoed J Boeser B Schuitemaker H Increased In Vitro Cytopathicity of CC Chemokine Receptor 5-Restricted Human Immunodeficiency Virus Type 1 Primary Isolates Correlates with a Progressive Clinical Course of Infection J Infect Dis 2003, 187(9):1397-1403 10.1086/374650 12717620
38. Scoggins RM Taylor JR Jr. Patrie J van't Wout AB Schuitemaker H Camerini D Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice J Virol 2000, 74(7):3205-3216 111821 10708437 10.1128/ JVI.74.7.3205-3216.2000
39. Berkowitz RD van't Wout AB Kootstra NA Moreno ME Linquist-Stepps VD Bare C Stoddart CA Schuitemaker H McCune JM R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus J Virol 1999, 73(9):7817-7822 104310 10438873
40. Kreisberg JF Kwa D Schramm B Trautner V Connor R Schuitemaker H Mullins JI van't Wout AB Goldsmith MA Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status J Virol 2001, 75(18):8842-8847 115129 11507229 10.1128/JVI.75.18.8842-8847.2001
41. Repits J Oberg M Esbjornsson J Medstrand P Karlsson A Albert J Fenyo EM Jansson M Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency J Gen Virol 2005, 86(Pt 10):2859-2869 10.1099/vir.0.81111-0 16186242
42. Karlsson I Antonsson L Shi Y Karlsson A Albert J Leitner T Olde B Owman C Fenyo EM HIV biological variability unveiled: Frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use AIDS 2003, 17(18):2561-2569 10.1097/00002030-200312050-00003 14685050
43. Dunfee RL Thomas ER Gorry PR Wang J Taylor J Kunstman K Wolinsky SM Gabuzda D The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia Proc Natl Acad Sci USA 2006, 103(41):15160-15165 1586182 17015824 10.1073/pnas.0605513103
44. Gorry PR Bristol G Zack JA Ritola K Swanstrom R Birch CJ Bell JE Bannert N Crawford K Wang H Schols D De Clercq E Kunstman K Wolinsky SM Gabuzda D Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity J Virol 2001, 75(21):10073-10089 114582 11581376 10.1128/JVI.75.21.10073-10089.2001
45. Gorry PR Taylor J Holm GH Mehle A Morgan T Cayabyab M Farzan M Wang H Bell JE Kunstman K Moore JP Wolinsky SM Gabuzda D Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate J Virol 2002, 76(12):6277-6292 136234 12021361 10.1128/JVI.76.12.6277-6292.2002
46. Peters PJ Bhattacharya J Hibbitts S Dittmar MT Simmons G Bell J Simmonds P Clapham PR Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages J Virol 2004, 78(13):6915-6926 421670 15194768 10.1128/JVI.78.13.6915-6926.2004
47. Chohan B Lang D Sagar M Korber B Lavreys L Richardson B Overbaugh J Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels J Virol 2005 79(10):6528-6531 1091724 15858037 10.1128/JVI.79.10.6528-6531.2005
48. Hu QX Barry AP Wang ZX Connolly SM Peiper SC Greenberg ML Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis J Virol 2000, 74(24):11858-11872 112469 11090186 10.1128/JVI.74.24.11858-11872.2000
49. Jansson M Backstrom E Scarlatti G Bjorndal A Matsuda S Rossi P Albert J Wigzell H Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates AIDS Res Hum Retroviruses 2001, 17(15):1405-1414 10.1089/ 088922201753197079 11679153
50. McCaffrey RA Saunders C Hensel M Stamatatos L N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies J Virol 2004, 78(7):3279-3295 371088 15016849 10.1128/JVI.78.7.3279-3295.2004
51. Milich L Margolin BH Swanstrom R Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein Virology 1997, 239(1):108-118 10.1006/ viro.1997.8821 9426451
52. Nabatov AA Pollakis G Linnemann T Kliphius A Chalaby MI Paxton WA Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies J Virol 2004, 78(1):524-530 303404 14671134 10.1128/JVI.78.1.524-530.2004
53. Sagar M Wu X Lee S Overbaugh J Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity J Virol 2006, 80(19):9586-9598 1617272 16973562 10.1128/JVI.00141-06
54. Shieh JT Martin J Baltuch G Malim MH Gonzalez-Scarano F Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains J Virol 2000, 74(2):693-701 111589 10623731 10.1128/JVI.74.2.693-701.2000
55. Teeraputon S Louisirirojchanakul S Auewarakul P N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies Viral Immunol 2005, 18(2):343-353 10.1089/vim.2005.18.343 16035946
56. Gray L Churchill MJ Keane N Sterjovski J Ellett AM Purcell DFJ Poumbourios P Kol C Wang B Saksena N Wesselingh SL Price P French M Gabuzda D Gorry PR Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoprotiens derived from two individuals homozygous for the CCR5 delta 32 allele J Virol 2006, 80(7):3684-3691 1440368 16537640 10.1128/JVI.80.7.3684-3691.2006
57. Ohagen A Devitt A Kunstman KJ Gorry PR Rose PP Korber B Taylor J Levy R Murphy RL Wolinsky SM Gabuzda D Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS J Virol 2003, 77(22):12336-12345 254258 14581570 10.1128/JVI.77.22.12336-12345.2003
58. Binley JM Wrin T Korber B Zwick MB Wang M Chappey C Stiegler G Kunert R Zolla-Pazner S Katinger H Petropoulos CJ Burton DR Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies J Virol 2004, 78(23):13232-13252 524984 15542675 10.1128/JVI.78.23.13232-13252.2004
59. Brown BK Darden JM Tovanabutra S Oblander T Frost J Sanders-Buell E de Souza MS Birx DL McCutchan FE Polonis VR Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01Æ, and CRF02_AG, for the development and assessment of candidate vaccines J Virol 2005, 79(10): 6089-6101 1091694 15857994 10.1128/JVI.79.10.6089-6101.2005
60. Bures R Gaitan A Zhu T Graziosi C McGrath KM Tartaglia J Caudrelier P El Habib R Klein M Lazzarin A Stablein DM Deers M Corey L Greenberg ML Schwartz DH Montefiori DC Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1 AIDS Res Hum Retroviruses 2000, 16(18):2019-2035 10.1089/088922200750054756 11153085
61. Hierholzer J Montano S Hoelscher M Negrete M Hierholzer M Avila MM Carrillo MG Russi JC Vinoles J Alava A Acosta ME Gianella A Andrade R Sanchez JL Carrion G Sanchez JL Russell K Robb M Birx D McCutchan F Carr JK Molecular Epidemiology of HIV Type 1 in Ecuador, Peru, Bolivia, Uruguay, and Argentina AIDS Res Hum Retroviruses 2002, 18(18):1339-1350 10.1089/088922202320935410 12487805
62. Li M Gao F Mascola JR Stamatatos L Polonis VR Koutsoukos M Voss G Goepfert P Gilbert P Greene KM Bilska M Kothe DL Salazar-Gonzalez JF Wei X Decker JM Hahn BH Montefiori DC Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies J Virol 2005, 79(6):10108-10125 1182643 16051804 10.1128/JVI.79.16.10108-10125.2005
63. Spudich SS Huang W Nilsson AC Petropoulos CJ Liegler TJ Whitcomb JM Price RW HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: A survey of subjects with viremia J Infect Dis 2005, 191(6):890-898 10.1086/428095 15717264
64. Liu SL Schacker T Musey L Shriner D McElrath MJ Corey L Mullins JI Divergent patterns of progression to AIDS after infection from the same source: Human immunodeficiency virus type 1 evolution and antiviral responses J Virol 1997, 71(6):4284-4295 191644 9151816
65. Kupfer B Sing T Schuffler P Hall R Kurz R McKeown A Schneweis KE Eberl W Oldenburg J Brackmann HH Rockstroh JK Spengler U Daumer MP Kaiser R Lengauer T Matz B Fifteen years of env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1 J Med Virol 2007, 79(11):1629-1639 10.1002/jmv.20976 17854039
66. Chen B Vogan EM Gong H Skehel JJ Wiley DC Harrison SC Structure of an unliganded simian immunodeficiency virus gp120 core Nature 2005, 433(7028):834-841 10.1038/nature03327 15729334
67. Zhou T Xu L Dey B Hessell AJ Van Ryk D Xiang SH Yang X Zhang MY Zwick MB Arthos J Burton DR Dimitrov DS Sodroski J Wyatt R Nabel GJ Kwong PD Structural definition of a conserved neutralization epitope on HIV-1 gp120 Nature 2007, 445(7129):732-737 10.1038/nature05580 17301785
68. Olivieri K Scoggins RM Bor YC Matthews A Mark D Taylor JR Jr. Chernauskas D Hammarskjold ML Rekosh D Camerini D The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1 Virology 2007, 358(1):23-38 10.1016/j.virol.2006.08.027 16999983
69. Price RW Neurological complications of HIV infection Lancet 1996, 348(9025):445-452 10.1016/S0140-6736(95)11035-6 8709786
70. Shieh JT Albright AV Sharron M Gartner S Strizki J Doms RW Gonzalez-Scarano F Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia J Virol 1998, 72(5):4243-4249 109654 9557714
71. Thomas ER Dunfee RL Stanton J Bogdan D Taylor J Kunstman K Bell JE Wolinsky SM Gabuzda D Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion Virology 2007, 360(1):105-119 10.1016/ j.virol.2006.09.036 17084877
72. Dunfee RL Thomas ER Wang J Kunstman K Wolinsky SM Gabuzda D Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia Virology 2007, 367(1):222-234 10.1016/j.virol.2007.05.029 17599380
73. Peters PJ Sullivan WM Duenas-Decamp MJ Bhattacharya J Ankghuambom C Brown R Luzuriaga K Bell J Simmonds P Ball J Clapham PR Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: Implications for transmission and pathogenesis J Virol 2006, 80(13):6324-6332 1488974 16775320 10.1128/JVI.02328-05
74. Dey B Pancera M Svehla K Shu Y Xiang SH Vainshtein J Li Y Sodroski J Kwong PD Mascola JR Wyatt R Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: Antigenicity, biophysics, and immunogenicity J Virol 2007, 81(11):5579-5593 1900256 17360741 10.1128/JVI.02500-06
75. Chang MI Panorchan P Dobrowsky TM Tseng Y Wirtz D Single-molecule analysis of human immunodeficiency virus type 1 gp120-receptor interactions in living cells J Virol 2005, 79(23):14748-14755 1287567 16282475 10.1128/JVI.79.23.14748-14755.2005
76. Steffens CM Hope TJ Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: Implications for HIV fusion and entry events J Virol 2004, 78(17):9573-9578 506925 15308751 10.1128/JVI.78.17.9573-9578.2004
77. Choe H Farzan M Sun Y Sullivan N Rollins B Ponath PD Wu L Mackay CR LaRosa G Newman W Gerard N Gerard C Sodroski J The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates Cell 1996, 85(7):1135-1148 10.1016/S0092-8674(00)81313-6 8674119
78. Xiang SH Farzan M Si Z Madani N Wang L Rosenberg E Robinson J Sodroski J Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody J Virol 2005, 79(10):6068-6077 1091675 15857992 10.1128/JVI.79.10.6068-6077.2005
79. Yang X Tomov V Kurteva S Wang L Ren X Gorny MK Zolla-Pazner S Sodroski J Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1 J Virol 2004, 78(23):12975-12986 525028 15542649 10.1128/JVI.78.23.12975-12986.2004
80. Deng HK Unutmaz D KewalRamani VN Littman DR Expression cloning of new receptors used by simian and human immunodeficiency viruses Nature 1997, 388(6639):296-300 10.1038/40894 9230441
81. Morgenstern JP Land H Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line Nucleic Acids Res 1990, 18(12):3587-3596 331014 2194165 10.1093/nar/18.12.3587
82. Platt EJ Wehrly K Kuhmann SE Chesebro B Kabat D Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1 J Virol 1998, 72(4):2855-2864 109730 9525605
83. Gao F Morrison SG Robertson DL Thornton CL Craig S Karlsson G Sodroski J Morgado M Galvao-Castro B von Briesen H Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization J Virol 1996, 70(3):1651-1667 189989 8627686
84. He J Chen Y Farzan M Choe H Ohagen A Gartner S Busciglio J Yang X Hofmann W Newman W Mackay CR Sodroski J Gabuzda D CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia Nature 1997, 385(6617):645-649 10.1038/385645a0 9024664
85. Gorry PR Dunfee RL Mefford ME Kunstman K Morgan T Moore JP Mascola JR Agopian K Holm GH Mehle A Taylor J Farzan M Wang H Ellery P Willey SJ Clapham PR Wolinsky SM Crowe SM Gabuzda D Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote Virology 2007, 362(1):163-178 10.1016/ j.virol.2006.11.025 17239419
86. Gorry PR Howard JL Churchill MJ Anderson JL Cunningham A Adrian D McPhee DA Purcell DF Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev J Virol 1999, 73(1):352-361 103840 9847339
87. Yang X Kurteva S Lee S Sodroski J Stoichiometry of antibody neutralization of human immunodeficiency virus type 1 J Virol 2005, 79(6):3500-3508 1075697 15731244 10.1128/JVI.79.6.3500-3508.2005
88. Yang X Wyatt R Sodroski J Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers J Virol 2001, 75(3):1165-1171 114022 11152489 10.1128/JVI.75.3.1165-1171.2001
89. Burton DR Barbas CF 3rd Persson MA Koenig S Chanock RM Lerner RA A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals Proc Natl Acad Sci USA 1991, 88(22):10134-10137 52882 1719545 10.1073/pnas.88.22.10134
90. Burton DR Pyati J Koduri R Sharp SJ Thornton GB Parren PW Sawyer LS Hendry RM Dunlop N Nara PL Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody Science 1994, 266(5187);1024-1027 10.1126/science.7973652 7973652
91. Muster T Guinea R Trkola A Purtscher M Klima A Steindl F Palese P Katinger H Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS J Virol 1994, 68(6):4031-4034 236911 7514684
92. Trkola A Pomales AB Yuan H Korber B Maddon PJ Allaway GP Katinger H Barbas CF 3rd Burton DR Ho DD Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG J Virol 1995, 69(11):6609-6617 189569 7474069
93. Trkola A Purtscher M Muster T Ballaun C Buchacher A Sullivan N Srinivasan K Sodroski J Moore JP Katinger H Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 J Virol 1996, 70(2):1100-1108 189917 8551569
94. Chen B Vogan EM Gong H Skehel JJ Wiley DC Harrison SC Determining the structure of an unliganded and fully glycosylated SIV gp120 envelope glycoprotein Structure 2005, 13(2):197-211 10.1016/j.str.2004.12.004 15698564
95. Huang CC Tang M Zhang MY Majeed S Montabana E Stanfield RL Dimitrov DS Korber B Sodroski J Wilson IA Wyatt R Kwong PD Structure of a V3-containing HIV-1 gp120 core Science 2005, 310(5750):1025-1028 10.1126/ science.1118398 16284180
96. Sobolev V Sorokine A Prilusky J Abola EE Edelman M Automated analysis of interatomic contacts in proteins Bioinformatics 1999, 15(4):327-332 10.1093/bioinformatics/15.4.327 10320401